SEARCH

SEARCH BY CITATION

REFERENCES

  • 1
    U.S. Food and Drug Administration. FDA News: FDA approves expanded use of HPV test. Available at http://www.fda.gov/bbs/topics/NEWS/2003/NEW00890.html. Accessed February 5, 2007.
  • 2
    Cuzack J, Mayrand MH, Ronco G, Snijders P, Wardle J. New dimensions in cervical cancer screening. Vaccine. 2006; 24S3: S390S397.
  • 3
    Bidus MA, Maxwell GL, Kulasingam S, et al. Cost-effectiveness analysis of liquid-based cytology and human papillomavirus testing in cervical cancer screening. Obstet Gynecol. 2006; 107: 9971005.
  • 4
    Maxwell GL, Carlson JW, Ochoa M, Krivak T, Rose GS, Myers ER. Costs and effectiveness of alternative strategies for cervical cancer screening in military beneficiaries. Obstet Gynecol. 2002; 100: 740748.
  • 5
    Kulasingam SL, Hughes JP, Kiviat NB, et al. Evaluation of human papillomavirus testing in primary screening for cervical abnormalities: comparison of sensitivity, specificity, and frequency of referral. JAMA. 2002; 288: 17491757.
  • 6
    Kim JJ, Wright TC, Goldie SJ. Cost-effectiveness of alternative triage strategies for atypical squamous cells of undetermined significance. JAMA. 2002; 287: 23822390.
  • 7
    Goldie SJ, Kim JJ, Wright TC. Cost-effectiveness of human papillomavirus DNA testing for cervical cancer screening in women aged 30 years or more. Obstet Gynecol. 2004; 103: 619631.
  • 8
    Kulasingam SL, Myers ER. Potential health and economic impact of adding a human papillomavirus vaccine to screening programs. JAMA. 2003; 290: 781789.
  • 9
    Dawson AE. Can we change the way we screen? The ThinPrep Imaging System: clinical trial data and early experience. Cancer Cytopathol. 2004; 102: 340344.
  • 10
    Dziura B, Quinn S, Richard K. Performance of an imaging system vs. manual screening in the detection of squamous intraepithelial lesions of the cervix. Acta Cytol. 2006; 50: 309311.
  • 11
    Lozano R. Comparison of computer-assisted and manual screening of cervical cytology. Gynecol Oncol. 2007; 104: 134138.
  • 12
    Berstein SJ, Sanchez-Ramos L, Ndubisi B. Liquid-based cervical cytologic smear study and conventional Papanicolaou smears: a metaanalysis of prospective studies comparing cytologic diagnosis and sample adequacy. Am J Obstet Gynecol. 2001; 185: 308317.
  • 13
    Abulafia O, Pezzullo JC, Shere DM. Performance of ThinPrep liquid-based cervical cytology in comparison with conventionally prepared Papanicolaou smears: a quantitative survey. Gynecol Oncol. 2003; 90: 137144.
  • 14
    Linder J, Zahnheiser D. The ThinPrep Pap Test: a review of clinical studies. Acta Cytol. 1997; 41: 3038.
  • 15
    Castle PE, Lorincz AT, Scott DR, et al. Comparison between prototype Hybrid Capture 3 and Hybrid Capture 2 human papillomavirus DNA assays for detection of high-grade cervical intraepithelial neoplasia and cancer. J Clin Microbiol. 2003; 41: 40224030.
  • 16
    McCullagh P, Nelder JA. Generalized Linear Models. 2nd ed. London: Chapman and Hall; 1989.
  • 17
    Cibas ES, Hong X, Crum CP, Feldman S. Age-specific detection of high risk HPV DNA in cytologically normal, computer-imaged ThinPrep Pap samples. Gynecol Oncol. 2007; 104: 702706.
  • 18
    Sellors JW, Mahony JB, Kaczorowski J, et al. Prevalence and predictors of human papillomavirus infection in women in Ontario, Canada. Survey of HPV in Ontario Women (SHOW) Group. CMAJ. 2000; 163: 503508.
  • 19
    Clavel C, Masure M, Bory JP, et al. Human papillomavirus testing in primary screening for the detection of high-grade cervical lesions: a study of 7932 women. Br J Cancer. 2001; 84: 16161623.
  • 20
    Zuna RE, Moore W, Dunn ST. HPV DNA testing of the residual sample of liquid-based Pap test: utility as a quality assurance monitor. Mod Pathol. 2001; 14: 147151.
  • 21
    Petry KU, Menton S, Menton M, et al. Inclusion of HPV testing in routine cervical cancer screening for women above 29 years in Germany: results for 8466 patients. Br J Cancer. 2003; 88: 1570157.
  • 22
    Kitchener HC, Almonte M, Wheeler P, et al. HPV testing in routine cervical screening: cross sectional data from the ARTISTIC trial. Br J Cancer. 2006; 95: 5661.
  • 23
    Ronco G, Segnan N, Giorgi-Rossi P, et al. Human papillomavirus testing and liquid-based cytology: results at recruitment from the New Technologies for Cervical Cancer randomized controlled trial. J Natl Cancer Inst. 2006; 98: 765774.
  • 24
    Cuzick J, Szarewski A, Cubie H, et al. Management of women who test positive for high-risk types of human papillomavirus: The HART Study. Lancet. 2003; 362: 18711876. Comments in: JFam Pract. 2004; 53: 266–268; Lancet. 2003; 362: 1866–1867.
  • 25
    Kovacic MB, Castle PE, Herrero R, et al. Relationships of human papillomavirus type, qualitative load, and age with cytologic abnormality. Cancer Res. 2006; 66: 1011210119.
  • 26
    Lorincz AT, Richart RM. Human papillomavirus DNA testing as an adjunct to cytology in cervical screening programs. Arch Path Lab Med. 2003; 127: 959968.
  • 27
    Mandelblatt JS, Lawrence WF, Womack SM, et al. Benefits and costs of using HPV testing to screen for cervical cancer. JAMA. 2002; 287: 23722381. Comment in: JAMA. 2002; 287: 2428–2429.
  • 28
    Gemmen K, Blackburne RE, van Engen AK, Partlow KL. A health economic model to determine the cost-effectiveness of cervical cancer screening methods. J Lower Gen Tract Dis. 2006; 10: 197A.
  • 29
    Sherman ME, Lorincz AT, Scott DR, et al. Baseline cytology, human papillomavirus testing, and risk for cervical neoplasia: a 10-year cohort analysis. J Natl Cancer Inst. 2003; 95: 4652.
  • 30
    Castle PE, Wacholder S, Lorincz AT, et al. A prospective study of high-grade cervical neoplasia risk among human papillomavirus-infected women. J Natl Cancer Inst. 2002; 94: 14061414.
  • 31
    Castle PE, Wacholder S, Sherman ME, et al. Absolute risk of subsequent abnormal Pap among oncogenic human papillomavirus DNA-positive cytologically negative women. Cancer. 2002; 95: 21452151.
  • 32
    Khan MJ, Castle PE, Lorincz AT, et al. The elevated 10-year risk of cervical precancer and cancer in women with human papillomavirus (HPV) type 16 or 18 and the possible utility of type-specific HPV testing in clinical practice. J Natl Cancer Inst. 2005; 97: 10721079.
  • 33
    Kjaer S, Hogdall E, Frederiksen K, et al. The absolute risk of cervical abnormalities in high-risk human papillomavirus-positive, cytologically normal women over a 10-year period. Cancer Res. 2006; 66: 1063010636.
  • 34
    Jastania R, Geddie WR, Chapman W, Boerner S. Characteristics of apparently false-negative digene hybrid capture 2 high-risk HPV DNA testing. Am J Clin Pathol. 2006; 125: 223228.
  • 35
    Stoler M, Castle PE, Solomon D, Schiffman M. The expanded use of HPV testing in gynecologic practice per ASCCP-guided management requires the use of well-validated assays. Am J Clin Pathol. 2007; 127: 335337.